Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 6/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.47 |
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.47 |
| ▸ | MCHR2 | Q969V1 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9910663 | 0.86 | CACNA1H (0.46) | MCHR1RAF1CACNA1HERBB2EGFR | |
| SCHEMBL29447563 | 0.86 | CACNA1H (0.46) | MCHR1RAF1CACNA1HERBB2EGFR | |
| SCHEMBL7981157 | 0.82 | PLA2G4A (0.54) | CACNA1H | |
| SCHEMBL1418153 | 0.81 | HDAC6 (0.51) | CACNA1HMAOAMAOB | |
| SCHEMBL7977924 | 0.80 | HDAC6 (0.55) | CACNA1HMAOAMAOB | |
| SCHEMBL24996628 | 0.79 | NPBWR1 (0.47) | MCHR1CACNA1H | |
| SCHEMBL30879430 | 0.79 | NPBWR1 (0.47) | MCHR1CACNA1H | |
| SCHEMBL31086654 | 0.79 | HDAC8 (0.48) | CACNA1H | |
| SCHEMBL28429755 | 0.79 | NPBWR1 (0.45) | MCHR1CACNA1H | |
| SCHEMBL20423953 | 0.79 | RECQL (0.54) | RAF1ERBB2EGFRERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018136935-A1 | 2-ARYLSULFONAMIDO-N-ARYLACETAMIDE DERIVATIZED STAT3 INHIBITORS | UNIVERSITY OF HAWAII (US) | 2018-07-26 | — | — | WO | disclosed |
| EP-2464228-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2017-12-06 | — | — | EP | disclosed |
| US-8552022-B2 | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2013-10-08 | — | — | US | disclosed |
| EP-2464228-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck Sharp & Dohme Corp. (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20120142706-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME LLC | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142706-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GPR27, GCGR | MCHR1 567/4885RAF1 3118/4885CACNA1H 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.